ARYx announced on July 7, 2009 data from the Phase 2/3 clinical trial of its novel, oral anticoagulant, tecarfarin (formerly ATI-5923), compared to the leading anticoagulant agent
A key unmet need in ACS is the lack of a flexible anticoagulant agent
that can be used regardless of whether a patient requires coronary intervention or is treated medically with pharmacological agents.
Food and Drug Administration (FDA) confirming that the existing development pathway remains acceptable to seek regulatory approval of ARYx's novel anticoagulant agent
, tecarfarin (ATI-5923).
ARYx expects to complete an out-licensing agreement in the near term for the clinical development and commercialization of its oral anti-arrythmic agent, budiodarone, and, following that, entering into similar agreements for its two other late stage products, ATI-7505, for the treatment of various gastrointestinal disorders, and tecarfarin, an oral anticoagulant agent
Ginkgo biloba has produced mixed results in patients with dementia and should be used with caution in those patients on concomitant warfarin or other anticoagulant agents
Reversal of coagulation defects is achieved through administration of anticoagulant agents
and replacement of blood factors.
Displays data elements characterizing active and recent dosing of all anticoagulant medications and provides recommendations for transitions between anticoagulant agents
Similar to our case, administration of antiplatelet and anticoagulant agents
could trigger massive bleeding even after a minor surgical procedure.
Idraparinux, a unique once a week synthetic pentasaccharide, is currently tested in phase III, against oral anticoagulant agents
, in various indications including the prevention of vascular events associated with atrial fibrillation.
There were no approved alternative anticoagulant agents
for patients with HIT undergoing PCI at the time the study was performed.
Since then, several new oral anticoagulant agents
have become available, including the direct thrombin inhibitor dabigatran (Pradaxa), and two factor Xa inhibitors--rivaroxaban (Xarelto) and apixaban (Eliquis)--which have been shown to be at least as effective as, if not more effective than, warfarin.
Oral Presentation Session: Anticoagulant Agents
Clinical Studies I